PSTV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
The historical rank and industry rank for Plus Therapeutics's Peter Lynch Fair Value or its related term are showing as below:
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
The historical data trend for Plus Therapeutics's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
Plus Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Peter Lynch Fair Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Plus Therapeutics's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's Price-to-Peter-Lynch-Fair-Value falls into.
Plus Therapeutics's Peter Lynch Fair Value for today is calculated as
Peter Lynch Fair Value | = | PEG Ratio | * | 5-Year TTM EBITDA Growth Rate** | * | EPS without NRI (TTM) |
= | 1 | * | N/A | * | -3.04 | |
= | N/A |
Plus Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Plus Therapeutics (NAS:PSTV) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.
Plus Therapeutics's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value | = | Share Price | / | Peter Lynch Fair Value |
= | 2.535 | / | N/A | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Plus Therapeutics's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Marc H Hedrick | officer: President | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Robert P Lenk | director | LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
Howard Clowes | director | 217 DWIGHT ROAD, BURLINGAME CA 94010 |
Greg Petersen | director | 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
Sims Andrew John Hugh Macintyre | officer: Chief Financial Officer | 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
Norman D. Lafrance | officer: CHIEF MEDICAL OFFICER | MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
Ag Postfinance | 10 percent owner | MINGERSTRASSE 20, BERN V8 3030 |
Bank Sa Swissquote | 10 percent owner | CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Ron Martell | director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Mark Marino | officer: Chief Medical Officer | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
John David Harris | officer: VP and GM of Cell Therapy | 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
David Rickey | director |
From GuruFocus
By Marketwired • 08-11-2023
By Marketwired • 10-09-2023
By Marketwired • 06-29-2023
By sperokesalga sperokesalga • 05-25-2023
By sperokesalga sperokesalga • 06-01-2023
By GuruFocus Research • 09-15-2023
By Marketwired • 08-08-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 05-16-2023
By sperokesalga sperokesalga • 05-30-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.